9 results about "Vascular proliferation" patented technology

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a composition in the preparation of a drug for treating diabetic wounds. The composition comprises the following components: *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone, with a mass ratio of 1:0.1-0.25:0.02-0.05. In this composition, *Artemisia capillaris* exosomes can penetrate the thickened inflammatory exudate layer and glycosylated extracellular matrix of diabetic wounds, reshaping the wound's immune repair microenvironment, promoting fibroblast activation and proliferation, regulating collagen synthesis and deposition, and reducing scar hyperplasia. 3-hydroxymorinogenone can increase vascular endothelial growth factor, promote angiogenesis, and thus promote the repair and healing of diabetic wounds. The synergistic effect of *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone in this composition significantly shortens the healing cycle of difficult-to-heal diabetic wounds and improves the quality of wound healing.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

The present invention relates to the technical field of medical materials. Provided are a topical cream or patch for scar treatment and a preparation method therefor. The cream or patch is a topical preparation for scar treatment that combines a hormone, an antibiotic and a chemotherapeutic drug. By means of the synergistic effect of the three components, the cream or patch realizes a variety of effects such as sterilization, anti-inflammation, inhibition of fibroblast proliferation and angiogenesis, inhibition of scar hyperplasia, promotion of scar softening, and prevention of infection, thereby improving the efficacy of scar treatment. The preparation can be simply applied topically or used as a patch without injection, which greatly facilitates patient use and achieves the aim of scar prevention and treatment, thereby providing a multi-functional, safe and effective approach for scar treatment.

A compound of Formula (I) is provided: (I) Salts and crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, inflammatory and fibrotic diseases, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

The invention relates to the technical field of biological medicine, in particular to ureido indolone compounds and a preparation method and application thereof. Compared with the prior art, the ureido indolone compound provided by the invention has the advantages that the activity of VEGFR, PDGFR and / or FGFR can be effectively inhibited, signal transduction of VEGF, PDGF and / or FGF is blocked, and systemic neovascularization (abnormal vascular hyperplasia) related diseases are treated.

The application discloses a preparation method and application of a multi-morphology fasudil targeted nanomedicine system for diabetes osteoarthritis, and belongs to the technical field of medicines, and comprises the following steps: 1) weighing free fasudil, dissolving the free fasudil in an organic phase solvent, fully stirring and dissolving, and preparing fasudil organic drug stock solution, which is marked as Fas; 2) slowly adding an acid solution to the Fas; the application takes free fasudil as an active drug, constructs Fas@PB-Sr 2+ The composite nano intermediate is subjected to CAP polypeptide targeted modification to obtain multi-morphology targeted nanoparticles. Through a low-temperature hydrothermal process, drug thermal degradation is avoided, square, rod, spherical and porous mesoporous composite morphologies are generated by regulating raw material ratio and reaction conditions, and cartilage specificity enrichment is realized in combination with the CAP polypeptide, multiple pathological damages such as cartilage wear, synovial inflammation and abnormal vascular hyperplasia of diabetes osteoarthritis are improved, joint local drug residence time is prolonged, and systemic drug toxic side effects are reduced.

A maleate salt of the compound of Formula (I) is provided: Crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; inflammatory or fibrotic diseases, cancer, epilepsy, Parkinson's disease, and Lafora disease.

The present invention relates to the field of drugs. Specifically, provided are an oligonucleotide targeting IRS-1 mRNA and use thereof in the preparation of a drug for preventing or treating vascular proliferation-related diseases or symptoms. By means of screening a series of antisense oligonucleotide sequences, it is found that when an oligonucleotide sequence contains a contiguous sequence that is substantially the same as GCTGCTGGTG, it has a significant and stable inhibitory effect on IRS-1 expression and angiogenesis under different modification modes. Said oligonucleotide can be used for preventing or treating vascular proliferation-related diseases or symptoms. Said oligonucleotide has broad application prospects.

The invention provides a pharmaceutical composition for adjuvant therapy of breast cancer and application thereof.The pharmaceutical composition comprises morinda citrifolia fermented juice freeze-dried powder, the morinda citrifolia fermented juice freeze-dried powder is prepared through a vacuum freeze-drying technology, and the effective dose of the morinda citrifolia fermented juice freeze-dried powder in adjuvant therapy of breast cancer is 3-12 mg / mL. The combined use of the morinda citrifolia fermented juice and gemcitabine can significantly inhibit the growth of breast cancer cells and vascular hyperplasia, has potential effects of improving chemotherapeutic drugs and reducing side effects of the chemotherapeutic drugs, is helpful to clarify the action mechanism of the morinda citrifolia fermented juice in treating breast cancer and the efficacy of combined chemotherapeutic drugs, and has broad application prospects. The medicinal value of the morinda citrifolia is actually converted into an anti-cancer drug or an auxiliary drug.